Cover Image
市場調查報告書

EpiCast Report:呼吸道融合病毒(RSV)感染疾病 - 到2024年的流行病學預測

EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 351420
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:呼吸道融合病毒(RSV)感染疾病 - 到2024年的流行病學預測 EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024
出版日期: 2015年12月23日 內容資訊: 英文 69 Pages
簡介

呼吸道融合病毒(RSV)感染疾病,是兒童的呼吸系統感染疾病的一般的原因,到2歲為止,幾乎所有兒童都有感染病毒的可能性。還有呼吸道融合病毒(RSV)感染疾病,也已知為成人呼吸疾病的重要原因。

本報告提供全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的呼吸道融合病毒(RSV)感染疾病調查分析,疾病的背景,危險因素和合併症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 呼吸道融合病毒(RSV)感染疾病的流行病學預測
    • 不滿2歲兒童的重症呼吸道融合病毒(RSV)感染疾病的風險群組
    • 早產
    • 新生兒CLD
    • 妊娠第3期 (後期) 的孕婦
    • 兒童的呼吸道融合病毒(RSV)感染疾病的住院
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

目錄
Product Code: GDHCER111-15

RSV is a common cause of pediatric respiratory infections, and virtually all children will have been infected by the virus by the age of two years. Also, RSV is recognized as an important cause of respiratory illness in adults. The majority of RSV infections present as mild upper respiratory illnesses that often self-resolve within two weeks, although about 1% of cases develop serious lower respiratory complications requiring hospitalization. In older adults, RSV can result in significant morbidity and mortality, and is easily transmissible in living facilities, such as nursing homes. Children under the age of two years and adults over 64 years of age, with certain health conditions, are most at risk for severe RSV infections, and it is therefore recommended that they receive prophylactic treatment.

In each of the 7MM, GlobalData epidemiologists determined that the prophylactic RSV population in 2014, which includes the preterm infant (less than 37 weeks gestational age) population that survived to 2 years of age, the population of infants with neonatal chronic lung disease (CLD), the population of children with congenital respiratory or neuromuscular diseases that compromise respiratory function, the population of children with hemodynamically significant congenital heart disease, and the population of third-trimester pregnant women, was highest for the US, followed by the 5EU (France, Germany, Italy, Spain, and UK) and Japan. This trend was also seen in the hospitalized RSV population, where the US had the highest number of confirmed and estimated RSV hospitalized cases in 2014, followed by the 5EU and Japan.

GlobalData epidemiologists provide a well-rounded, evidence-based historical trend analysis and population forecast for the RSV prophylactic and hospitalized populations. This analysis covered all at-risk groups that are recommended for RSV prophylactic treatment. Each population, including the hospitalized population, was also segmented by ages (0 years, 1 year, and 2 years) and by sex, thereby providing a granular visualization of the RSV prophylactic and hospitalized market in the 7MM. Furthermore, the forecast is based on an in-depth analysis of a comprehensive set of factors that may impact the RSV prophylactic and hospitalized populations. These factors include trends in population changes, births, preterm births, infant mortality, and the disease incidence, prevalence, and mortality.

Scope

  • The Respiratory Syncytial Virus (RSV) Infection EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for RSV infection in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the for the pediatric population hospitalized due to RSV infection (hospitalized population), in addition to the pediatric and adult populations that are most at risk for severe RSV infection and are therefore eligible to receive prophylactic treatment (prophylactic population) in these markets.
  • The RSV epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The RSV EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global RSV market.
  • Quantify patient populations in the global RSV market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for RSV prophylactics and therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. Preterm Infants and Children Born Preterm and Survived to Two Years of Age
    • 3.3.2. Infants with Neonatal CLD
    • 3.3.3. Children with Hemodynamically Significant Congenital Heart Disease
    • 3.3.4. Children with Congenital Respiratory or Neuromuscular Diseases That Compromise Respiratory Function
    • 3.3.5. Third-Trimester Pregnant Women
    • 3.3.6. Hospitalizations for RSV Infection
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for RSV Infection (2014-2024)
    • 3.5.1. Risk Groups for Severe RSV Infection in Children Less than Two Years
    • 3.5.2. Preterm Births
    • 3.5.3. Neonatal CLD
    • 3.5.4. Third-Trimester Pregnant Women
    • 3.5.5. RSV Hospitalizations in Children
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Severe RSV Infection
  • Table 2: 7MM, Sources Used to Determine the Preterm Infant Population, 2014
  • Table 3: 7MM, Sources Used to Determine the Incidence of Neonatal CLD, 2014
  • Table 4: 7MM, Sources Used to Determine the Incidence of Hemodynamically Significant Heart Disease in Children, 2014
  • Table 5: 7MM, Sources Used to Determine the Diagnosed Prevalence of Congenital Respiratory and Neuromuscular Diseases That Compromise Respiratory Function in Children, 2014
  • Table 6: 7MM, Sources Used to Determine the Third-Trimester Pregnant Women Population, 2014
  • Table 7: NICHD Neonatal CLD Severity Categorization
  • Table 8: 7MM, Children at Risk for Severe RSV Infection, Boys and Girls, Ages ≤2 Years, N, 2014
  • Table 9: 7MM, Children at Risk for Severe RSV Infection, Boys and Girls, Ages ≤2 Years, N, 2024
  • Table 10: 7MM, Preterm Births, Boys and Girls, <37 Weeks' GA, N (Row %), 2014
  • Table 11: 7MM, Incident Cases of Neonatal CLD by Severity, Boys and Girls, <32 Weeks GA, N (Row %), 2014
  • Table 12: 7MM, Third-Trimester Pregnant Women, N, 2014 and 2024
  • Table 13: 7MM, Confirmed RSV Hospitalizations in Children, Ages 0-2 Years, N, 2014
  • Table 14: 7MM, Estimated RSV Hospitalizations in Children, Ages 0-2 Years, N, 2014

List of Figures

  • Figure 1: Case Flow Map for RSV Prophylactic and Therapeutic Populations
  • Figure 2: Population Estimates and Births Forecast for the US, Boys and Girls, 1997-2024
  • Figure 3: 7MM, Children Born Preterm (<37 Weeks' GA) Surviving to Ages 0-2 Years, Boys and Girls, N, 2014 and 2024
  • Figure 4: 7MM, Children at Risk for Severe RSV Infection, Boys and Girls, Ages ≤2 Years, N, 2014
  • Figure 5: 7MM, Children at Risk for Severe RSV Infection, Boys and Girls, Ages ≤2 Years, N, 2024
Back to Top